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5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors
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Summary This study evaluated the relationship between prechemotherapy cortisol and 5-hydroxyindoleacetic
acid (5-HIAA) excretion and chemotherapy-induced emesis. The urinary excretion ofcortisol and the serotonin
metabolite 5-HIAA in the night before chemotherapy administration were measured in 28 and 49 female
patients receiving >300 mg m-2 carboplatin. Vomiting and nausea were documented over a 3 day observation
period. Lower basal cortisol excretion was significantly correlated with vomiting with or without nausea
occurring within the observation period. 5-HIAA showed only a weak correlation with emesis on days 1-3,
but low 5-HIAA excretion was correlated with a higher proportion ofpatients vomiting on days 2 -3 following
chemotherapy. Low basal cortisol excretion might be useful as a predictor for chemotherapy-induced emesis
and therefore should be evaluated prospectively in future studies.
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Vomiting and nausea are distressing side-effects of cytostatic
drug treatment (Coates et al., 1983) and efficient anti-emetic
prophylaxis is mandatory for the maintenance of life quality
and the patients' compliance with chemotherapy. Cisplatin,
carboplatin and cyclophosphamide are widely used cyto-
statics which possess a remarkable emetogenic potential.
Treatment without anti-emetic prophylaxis leads to emesis in
the majority of patients (Gralla et al., 1981; Martin et al.,
1990; Beck et al., 1993). The combination of 5-hydroxy-
tryptamine-3-receptor (5-HT3) antagonists with corticoster-
oids represents the most effective anti-emetic treatment in
platinum-based and cyclophosphamide-based chemotherapy
(Roila et al., 1991; Italian Group for Antiemetic Research,
1995). These clinical experiences as well as experimental data
(Cubeddu et al., 1990; Schworer et al., 1991; Miner et al.,
1987; Fredrickson et al., 1992) indicate a role for serotonin
and corticosteroid metabolism in the pathophysiology of
emesis. The mechanism of anti-emetic action of the 5-HT3
antagonists mainly reflects their capability of blocking 5-HT3
receptors which are believed to play a crucial role in the
afferent part of the emetic reflex. The mechanisms of the anti-
emetic action of corticosteroids are still unclear: increased 5-
HT turnover or reduced 5-HT synthesis (Young, 1981;
Munck et al., 1984) or an affection of the permeability of
the blood -brain barrier (Livera et al., 1985) are in
discussion. However, neither 5-HT3 receptor antagonists nor
corticosteroids provide complete control of chemotherapy-
induced emesis in all patients and there is a remarkable
interindividual variation of susceptibility to emetogenic
stimuli. The individual predisposition for emesis is deter-
mined by not yet completely described risk factors.
Two groups of risk factors for chemotherapy-induced
emesis have been identified: factors related to the chemother-
apy regimen and those related to the individual patient. The
first group contains the type of cytostatics used, the
combination of different drugs and the chemotherapy dose.
The second group contains gender, age, history of alcohol
intake, susceptibility for motion sickness, chemotherapy
experience and biochemically measurable parameters such
as noradrenaline (Fredrickson et al., 1994) and cortisol
(Fredrickson et al., 1992; Hursti et al., 1993). However,
methodological problems of the latter studies make it difficult
to draw final conclusions regarding the relation between
cortisol metabolism and emesis. The major methodological
problems in the Scandinavian studies were: patients with
single-day and multiple-day chemotherapy regimens were not
analysed separately, the sample collection period was not
standardised and the analysis of emesis was performed
between patients with 0-2 vs >2 emetic episodes instead
of patients with and without emesis.
The aim of this study was to evaluate the relation between
pre-chemotherapeutic 5-HIAA and cortisol excretion levels
and chemotherapy-induced emesis in carboplatin-treated
female patients. This analysis should add information about
the role of 5-HT and cortisol metabolism in the pathophy-
siology of chemotherapy-induced emesis.
Methods
Patients
A total of 54 patients who received a carboplatin-based
chemotherapy regimen gave informed consent and were
enrolled into the study. Five patients were excluded because
they had failed to complete the 12 h urine collection. Data
from 49 patients were evaluable for 5-HIAA measurement
and cortisol was evaluated in 28 of these patients.
Chemotherapy consisted of carboplatin >300 mg m-2 as a
single-day, 1 h infusion. Combination with alkylating agents
was allowed when administered on the same day. Patient
characteristics are shown in Table I. A total of 17 patients
received carboplatin 400-420 mg m-2 as single agent
therapy, 16 patients received 350 mg ml-2 carboplatin
combined with 600 mg m-2 cyclophosphamide and 16
patients received 300 mg m-2 carboplatin combined with
2.5-5.0 g m-2 ifosfamide. Anti-emetic treatment consisted of
8 mg ondansetron intravenous (i.v.) single-agent therapy
starting 15-30 min before chemotherapy followed by 8 mg
ondansetron orally for 1-3 days. All patients had diagnosed
gynaecological cancer. The median age was 54.5 years and
57.3 years in all patients and the patients in whom cortisol
was evaluated respectively. Patients were treated as inpatients
for the whole 3 day observation period. Emesis was defined
as vomiting or retching. Nausea was recorded on a 4 point
scale (none, mild, moderate or severe). Patients were
considered to suffer from nausea if they had documented
more then mild nausea within the observation period.
Patients were observed by study nurses and each episode of
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emesis was documented. Furthermore, patients were given
diaries and asked to document each episode ofemesis and the
grade of nausea for each day separately. Patients with
impaired renal function or endocrinological disorders were
excluded. None of the patients had a history ofheavy alcohol
consumption. Patients were asked to avoid serotonin-rich
food like bananas or nuts the day before chemotherapy.
Sample collection and analysis
The prechemotherapeutic urine samples were collected in a
standardised time period from 20.00 to 08.00 the night before
chemotherapy. The urine was stored in dark containers and
the volume was recorded. A 10 ml aliquot was taken at the
end of the collection period and frozen at -20°C until
measurement. All measurements were performed with
commercially available immunological assays. Cortisol was
measured with a solid-phase fluorescence immunoassay
(Delfia Cortisol kit, Kabi Pharmacia). No pretreatment was
needed for this measurement procedure. Urine (20 Ml) was
directly inserted and each sample was analysed twice for the
purpose of internal control. The intra-assay variation
coefficients were < 10% and the interassay variation
coefficients were < 12% as measured with Lyophocheck
quality controls (Biorad). 5-Hydroxyindoleacetic acid (5-
HIAA) was measured with a fluorescence polarisation
immunoassay (5-HIAA FPIA kit, Abbott Diagnostics). The
preparation procedures of the urine samples are reported
elsewhere (du Bois et al., 1995). Every measurement series
was accompanied by an internal control. Intra-assay
variation coefficients were <10% and interassay variation
coefficients were <8%.
The measured concentrations were multiplied by the urine
volume to calculate the amounts of 5-HIAA and cortisol
excreted over 12 h the night before chemotherapy. Analysis
was based on the comparisons between patients with and
without emesis and between patients with and without emesis
and/or nausea. Emesis and emesis with or without nausea
were analysed separately for day 1, days 2-3 and days 1-3.
The relationship between emesis and the quantitative
variables of cortisol and serotonin metabolism was analysed
in two ways. First we compared patients with or without
emesis with respect to the distribution of the measured
variables by using boxplots (retrospective analysis). Signifi-
cance was tested by the Wilcoxon test. Second, we considered
the probability of emesis as a function of the quantitative
variables (prospective analysis). These functions are shown by
a running mean smoother. Corresponding P-values were
based on the Spearman correlation coefficient.
Results
Emesis was observed in 37% of all patients on days 1-3. On
the day ofchemotherapy (day 1) 16% showed vomiting while
31% suffered from at least one emetic episode on days 2-3.
Vomiting and/or nausea occurred more frequently. In all 49%
ofpatients suffered from vomiting with or without nausea on
days 1-3. Altogether 41% and 33% of patients showed
vomiting with or without nausea on day 1 and days 2-3
respectively. The subgroup of patients in whom cortisol was
analysed showed emesis on day 1 in 14%, emesis on days 1-3
in 43% and emesis on days 2-3 in 43%. Emesis with or
without nausea was observed in 36% on day 1, 50% on days
1-3 and 50% on days 2-3 respectively. All patients who
vomited on days 2-3 had also vomited on day 1. Therefore,
analysis of emesis on days 1-3 and emesis on days 2-3
showed similar results in the subgroup of patients in whom
cortisol excretion was analysed. However, the results are
presented separately to make them comparable with the
results of the 5-HIAA group. In the latter group some
patients started vomiting later than day 1 and results
regarding emesis on days 1-3 differ from results based on
the analysis of emesis on days 2-3.
5-Hydroxyindoleacetic acid (5-HIAA)
The retrospective comparison of pretherapeutic 5-HIAA
excretion did not reveal any significant differences between
patients with and without emesis and/or nausea over days 1-
3 (Figure 1c). Median 5-HIAA excretion was 267 Mg with
25-75% quartiles being 187-313 ,ug in patients with emesis,
and 230 Mg (155-325 Mg) in patients without emesis and/or
nausea (P=0.54). Again, analysis with respect to emesis and/
or nausea on day 1 showed no significant difference (P=0.48;
Figure la). In contrast, the comparison between patients with
and without emesis and/or vomiting on days 2-3 reveals a
significant difference with lower 5-HIAA excretion levels in
patients suffering from nausea and/or vomiting (Figure lb).
5-HIAA excretion levels were 200 Mg (126-238 Mg) and
275 Mg (198-328 Mg) in patients with and without emesis
and/or nausea on days 2-3 (P=0.02). The comparison
between patients with and without vomiting showed similar
results and confirmed a relationship between vomiting on
days 2-3 and pretherapeutic 5-HIAA excretion levels. Owing
to the smaller numbers of events (i.e. emetic episodes)
significance was not reached (P=0.057).
Figure 2 shows the relationship between prechemother-
apeutic 5-HIAA excretion levels and vomiting with or
without nausea on days 1-3. Considering the whole
observation period no correlation between 5-HIAA values
and emesis was detected. The relationship was stronger when
only vomiting was analysed but failed to reach significance
(P=0.11). Emesis and/or nausea as well as only vomiting on
day 1 did not show any correlation with pretherapeutic 5-
HIAA excretion levels. P-values are 0.93 and 0.48 for the
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Figure 1 Prechemotherapy 5-HIAA excretion in patients with or
without carboplatin-induced emesis +/- nausea on day 1 (a),
days 2-3 (b) and days 1-3 (c) (median and 25-75% quartiles).
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Figure 2 Relationship between basal 5-HIAA excretion and
emesis +/- nausea on days 1-3 following carboplatin-based
chemotherapy. (-C1-), running mean (range 11); P= 0.54.
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4 _%% Fcorrelation between 5-HIAA and vomiting and vomiting with
or without nausea on day 1. The analysis of the relationship
between 5-HIAA excretion and vomiting or vomiting with or
without nausea on days 2-3 showed a trend for higher 5-
HIAA values in patients who did not vomit with P-values of
0.055 and 0.017 respectively. In summary, prospective
analysis revealed only a correlation between pretherapeutic
5-HIAA excretion and emesis or emesis with or without
nausea on days 2-3.
Cortisol
Cortisol excretion was significantly lower in patients who
developed emesis with or without nausea on days 1-3
(Figure 3c). Median cortisol excretion levels were 84 Mug (27-
104 jg) and 136 ,ug (66-188 jg) in patients with and without
vomiting and/or nausea (P=0.03). As all patients who
vomited on days 2-3 also vomited on day 1, the analysis
of emesis with or without nausea on days 2-3 gave the same
results (P=0.03; Figure 3b). The analysis regarding patients
with or without vomiting and/or nausea on day 1 showed
only a slight trend in favour of a higher cortisol excretion in
patients who did not vomit (P=0.28; Figure 3a). The
comparison regarding vomiting only for each observation
period gave similar results (data not shown).
Figure 4 shows the relation between pretherapy cortisol
levels and emesis with or without nausea on days 1-3. There
was a significant correlation between low cortisol values and
a high risk for emesis with or without nausea. Corresponding
P-values are 0.049 and 0.026 for vomiting and vomiting with
or without nausea respectively. Analysis of vomiting with or
without nausea on day 1 did not reveal a similarly strong
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correlation with cortisol values (P= 0.27). The latter analysis
was hampered by the small numbers ofevents on day 1. Only
four patients of the cortisol group vomited on day 1. Again,
the analysis of days 2-3 coincided with that of days 1-3.
The correlation between low cortisol levels and a higher risk
for emesis was confirmed by the observation that vomiting
within days 1-3 occurred only in patients with a cortisol
excretion level below 110 jMg 12 h-1. In summary, low cortisol
excretion level showed a close relation to emesis occurring
within the 3 days following carboplatin-based chemotherapy.
Discussion
The involvement of 5-HT in the pathophysiology of
chemotherapy-induced emesis has been documented in
several studies. Particularly for cisplatin therapy, experi-
mental as well as clinical data have contributed to the actual
model of the pathophysiology of emesis. In short, cisplatin
leads to an exocytotic release of 5-HT from the enterochro-
maffine cells in the upper gut which then binds to vagal 5-
HT3 receptors causing depolarisation. The activation of
afferent vagal neurones leads to a stimulation of brainstem
neurones, the so-called 'vomiting centre'. The activation of
the 'vomiting centre' starts a cascade of efferent activity
which finally evokes emesis (for a review see Andrews, 1994).
Correspondingly, an increased excretion of 5-HIAA, the main
metabolite of 5-HT, following cisplatin therapy has been
observed (Cubeddu et al., 1992). 5-HT3 receptor antagonists
did not diminish 5-HIAA excretion following cisplatin
chemotherapy (du Bois et al., 1995).
But 5-HT3 receptor antagonists do not provide complete
control of chemotherapy-induced emesis and there is a
remarkable interindividual and sometimes intra-individual
variation with respect to the severity of emesis following
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Figure 3 Prechemotherapy cortisol excretion in patients with or
without carboplatin-induced emesis on day 1 (a), days 2-3 (b)
and days 1-3 (c) (median and 25-75% quartiles).
Table I Characteristics of all patients (5-HIAA evaluation, n =49)
and the subgroup ofpatients in whom cortisol was evaluated (n =28)
5-HIAA Cortisol
No. of patients 49 28
Age (years) 54.4 (26-77) 59 (35-77)
Prior CT 71% 75%
Diagnosis
Cervical cancer 16 7
Ovarian cancer 33 21
CT regimen
Carboplatin single agent 17 14
Carboplatin-CTX 16 9
Carboplatin-IFO 16 5
Median carboplatin dose 350 mg m-2 375 mg m72
CT, chemotherapy; CTX, cyclophosphamide; IFO, ifosfamide.
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Figure 4 Relationship between basal urinary cortisol excretion
and emesis +/ - nausea on days 1 -3 following carboplatin-based
chemotherapy. (-EO-), running mean (range 11); P=0.026.
Table II Risk of vomiting and vomiting + nausea for low vs high
urinary cortisol and 5-HIAA excretion
Cortisol 5-HIAA
OR CI OR CI
Vomiting
Day 1 2.54 0.23-28.02 2.86 0.51-15.85
Day 1-3 8.33 1.34-51.67 4.85 1.29-18.15
Day 2-3 8.33 1.34-51.67 5.07 1.21-21.28
Vomiting+
nausea
Day 1 2.33 0.45-12.00 1.16 0.37-3.61
Day 1-3 6.00 1.15-31.23 1.81 0.58-5.64
Day 2-3 6.00 1.15-31.23 5.88 1.40-24.64
Cut-off values are 101 Mg 12 h-1 and 260 jg 12 h-1 for cortisol and
5-HIAA respectively.
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relatively uniform emetogenic stimuli. The mechanisms
underlying the variability of emetic reaction are based on
individual risk profiles in each patient at each time. Based on
the assumption that both 5-HT and cortisol play a crucial
role in the pathophysiology of vomiting, it seems likely that
interindividual variations concerning the metabolism of these
mediators contribute to the individual risk profile of each
patient. In order to evaluate the role of serotonin metabolism
in emesis, post-chemotherapy 5-HIAA excretion levels have
been analysed: Cubeddu et al. (1992) and our own laboratory
(du Bois et al., 1995) found elevated 5-HIAA excretion levels
following platinum-based chemotherapy, but could not
demonstrate any difference in post-chemotherapy 5-HIAA
excretion depending on whether a patient vomits or not. The
present study has evaluated prechemotherapeutic 5-HIAA
excretion levels and emesis. 5-HIAA excretion showed only
marginal differences between patients who vomited and those
who did not when the whole observation period is considered
for analysis. However, low 5-HIAA excretion might be
related to emesis occurring on days 2-3 following
carboplatin. These data make it worthwhile to evaluate
further the role of serotonin in the pathophysiology of non-
cisplatin-induced emesis occurring later than on day 1.
Corticoid metabolism is probably also involved in the
pathophysiology of chemotherapy-induced emesis. Corticos-
teroids have shown a remarkable anti-emetic efficacy and a
relationship between anti-emetic efficacy of corticosteroids
and lower basal cortisol excretion has been reported (Hursti
et al., 1993). The present data in carboplatin-treated female
patients confirm these findings and indicate a close relation-
ship between cortisol excretion levels and the risk of emesis.
Again, the correlation between lower cortisol excretion and
emesis is weaker when analysis is limited to day 1.
Cortisol excretion levels were superior to 5-HIAA values
in predicting carboplatin-induced emesis and might be useful
in the description of the individual risk for chemotherapy-
induced emesis. The analysis of the relationship between
cortisol and emesis was based on a retrospectively defined
cut-off. Therefore, results might be too optimistic. However,
the present analysis helps to identify risk factors which
should be considered for further studies. Our data are
preliminary because only a selected group of patients (i.e.
females) was enrolled. Nevertheless, this study can help
design future protocols evaluating cortisol excretion prospec-
tively. These future studies should help to define the role of
cortisol excretion levels as risk factors and predictors of
chemotherapy-induced emesis.
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